Improvement of Hepatic and Extrahepatic Complications from Chronic Hepatitis C After Antiviral Treatment: A Retrospective Analysis of German Sickness Fund Data

[1]  M. Mizokami,et al.  Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan , 2018, Journal of viral hepatitis.

[2]  H. Kleine,et al.  Clinical and Economic Burden of Hepatic and Extrahepatic Complications from Chronic Hepatitis C: A Retrospective Analysis of German Sickness Fund Data , 2018, Infectious Disease and Therapy.

[3]  M. Charafeddine,et al.  Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R + Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical Trials , 2017, Infectious Diseases and Therapy.

[4]  F. Kanwal,et al.  Hepatitis C and Risk of Nonhepatic Malignancies. , 2017, Clinics in liver disease.

[5]  F. Vekeman,et al.  Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy , 2017, Hepatology communications.

[6]  R. Aggarwal,et al.  Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India , 2017, PloS one.

[7]  R. Brookmeyer,et al.  Economic study of the value of expanding HCV treatment capacity in Germany , 2017, BMJ open gastroenterology.

[8]  F. Negro,et al.  The impact of hepatitis C virus outside the liver: Evidence from Asia , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[9]  I. Miziara,et al.  Extrahepatic manifestations of chronic hepatitis C infection: a consecutive study in Brazilian patients , 2016, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[10]  R. Nuño Solinís,et al.  Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence , 2016, Infectious Diseases and Therapy.

[11]  M. Buti,et al.  Análisis coste-efectividad de sofosbuvir, interferón pegilado y ribavirina en pacientes con hepatitis crónica por virus C: tratamiento precoz en fases iniciales de fibrosis vs. tratamiento tardío en fases avanzadas , 2016 .

[12]  S. Petta.  Hepatitis C virus and cardiovascular: A review , 2016, Journal of advanced research.

[13]  M. Stepanova,et al.  Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. , 2016, Gastroenterology.

[14]  C. Graham,et al.  Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States , 2016, Infectious Agents and Cancer.

[15]  R. Brookmeyer,et al.  Value of expanding HCV screening and treatment policies in the United States. , 2016, The American journal of managed care.

[16]  C. Camma',et al.  Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective? , 2016, Clinical Drug Investigation.

[17]  P. Cacoub,et al.  Extrahepatic manifestations of chronic hepatitis C virus infection , 2016, Therapeutic advances in infectious disease.

[18]  R. Brookmeyer,et al.  Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern. , 2015, Health affairs.

[19]  H. Razavi,et al.  Global epidemiology and genotype distribution of the hepatitis C virus infection. , 2014, Journal of hepatology.

[20]  M. Carrozzo,et al.  Oral manifestations of hepatitis C virus infection. , 2014, World journal of gastroenterology.

[21]  G. Esmat,et al.  The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm , 2014, Journal of viral hepatitis.

[22]  Z. Cheng,et al.  Extrahepatic manifestations of chronic hepatitis C virus infection: 297 cases from a tertiary medical center in Beijing, China , 2014, Chinese medical journal.

[23]  R. Marinho,et al.  Benefits of curing hepatitis C infection. , 2014, Journal of gastrointestinal and liver diseases : JGLD.

[24]  M. Thamm,et al.  [Epidemiology of hepatitis A, B, and C among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. , 2013, Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz.

[25]  I. Colle,et al.  Resource use and cost of hepatitis C-related care , 2012, European journal of gastroenterology & hepatology.

[26]  A. Gamal,et al.  Prevalence of rheumatologic manifestations of chronic hepatitis C virus infection among Egyptians , 2010, Clinical Rheumatology.

[27]  G. Treisman,et al.  Medical Consequences of Drug Abuse and Co-Occurring Infections , 2008, Substance abuse.

[28]  K. Wijarnpreecha,et al.  Hepatitis C virus infection and risk of Parkinson’s disease: a systematic review and meta-analysis , 2018, European journal of gastroenterology & hepatology.

[29]  Z. Younossi,et al.  Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection , 2017 .

[30]  F. Schut,et al.  Free choice of sickness funds in social health insurance-theoretical foundation and empirical findings in Germany , 2002 .